A company that designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. anticipates two regulatory approvals for berotralstat in 2020,

Even more impressive, that BCRX will likely get a significant near-term boost from the success of GILD's remdesivir in the treatment of COVID-19. it will help us a lot to conquer against the PANDEMIC. let the BULLS trend here!
BCRXBeyond Technical AnalysisDJITechnical IndicatorsNasdaq Composite Index CFDSPX (S&P 500 Index)Trend AnalysisVIX CBOE Volatility Index

Declinazione di responsabilità